Anavex Life Sciences Corp (AVXL)

[BIOChecker4]

Horse pucky. The Neuren/Acadia Phase 2 data were very strong and Neurology, a highly respected peer-reviewed publication, chose to publish the study: https://n.neurology.org/content/92/16/e1912.
--------------------------------------------------------------------
Excerpts from the Neurology article follow:

Results All dose levels were well tolerated and generally safe. Trofinetide at 200 mg/kg bid showed statistically significant and clinically relevant improvements relative to placebo on the Rett Syndrome Behaviour Questionnaire, RTT-Clinician Domain Specific Concerns–Visual Analog Scale, and Clinical Global Impression Scale–Improvement. Exploratory analyses suggested that observed changes correlated with trofinetide exposure.

Conclusion These results, together with those from a previous adolescent/adult trial, indicate trofinetide's potential for treating core RTT symptoms and support further trials.

Classification of evidence This study provides Class I evidence that for children/adolescents with RTT, trofinetide was safe, well-tolerated, and demonstrated improvement over placebo at 200 mg/kg bid in functionally important dimensions of RTT.